Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

268
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
268
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

674
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
674
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

4.0K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
4.0K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

664
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
664
The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

1.1K
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
1.1K
One-Way ANOVA: Equal Sample Sizes01:15

One-Way ANOVA: Equal Sample Sizes

4.2K
One-Way ANOVA can be performed on three or more samples with equal or unequal sample sizes. When one-way ANOVA is performed on two datasets with samples of equal sizes, it can be easily observed that the computed F statistic is highly sensitive to the sample mean.
Different sample means can result in different values for the variance estimate: variance between samples. This is because the variance between samples is calculated as the product of the sample size and the variance between the...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic effects of robot-assisted surgery and enhanced recovery after surgery protocols on outcomes of femoral neck fracture fixation: a comparative cohort study.

Journal of robotic surgery·2026
Same author

Development of a hydrazinolysis method for the determination of vinclozolin in foods by SPE and GC-MS/MS.

Food chemistry·2026
Same author

Detecting the Pre-Disease State of Single Sample Through the Change in Local Network Enrichment Level.

Genes·2026
Same author

Study on the inhibition of thyroid undifferentiated carcinoma metastasis by nanoparticles loaded with EZH2 inhibitor.

Translational cancer research·2026
Same author

Empowerment-based case management for treatment-resistant schizophrenia: a three-year single case report.

Frontiers in psychiatry·2026
Same author

A novel integrative machine learning-based prognostic model reveals lactylation regulation in hepatocellular carcinoma progression.

Cancer cell international·2026

Related Experiment Video

Updated: Mar 2, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K

Comparison of proportions for composite endpoints with missing components.

Xianbin Li1, Brian S Caffo

  • 1U.S. Food and Drug Administration, Silver Spring, Maryland, USA. xianbin.li@fda.hhs.gov

Journal of Biopharmaceutical Statistics
|March 11, 2011
PubMed
Summary

This study introduces a new statistical method for handling missing data in composite endpoints within clinical trials. The developed methods provide accurate estimates and satisfactory performance, even with moderate sample sizes.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Related Experiment Videos

Last Updated: Mar 2, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.7K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Statistical Modeling

Background:

  • Composite endpoints are frequently used in clinical trials to assess treatment efficacy.
  • Missing data in composite endpoint components can lead to biased or inefficient trial results.
  • Proper handling of missingness is crucial for reliable estimation of treatment effects.

Purpose of the Study:

  • To develop a maximum likelihood estimator for the proportion of successes in a three-component composite endpoint with missing values.
  • To derive closed-form variance for the proportion and compare two groups using difference in proportions and log relative risk.
  • To evaluate the performance of the developed statistical methods through simulation studies.

Main Methods:

  • Maximum likelihood estimation for composite endpoints with missing data.
  • Derivation of closed-form variance for estimated proportions.
  • Comparison of two groups via difference in proportions and log relative risk.
  • Simulation studies to assess method performance and power.

Main Results:

  • The developed maximum likelihood estimator provides accurate estimates for composite endpoints with missing data.
  • The methods demonstrated satisfactory performance and statistical power in simulation studies.
  • The approach is effective even with moderate sample sizes, addressing common challenges in clinical trial analysis.

Conclusions:

  • The proposed statistical methods effectively handle missing data in three-component composite endpoints.
  • These methods offer a robust approach for estimating treatment effects and comparing groups in clinical trials.
  • The findings support the use of these techniques for improved efficiency and reduced bias in clinical trial data analysis.